Cel-Sci Common Stock Net 2010-2025 | CVM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cel-Sci common stock net from 2010 to 2025. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cel-Sci common stock net from 2010 to 2025. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$229.3B
Amgen (AMGN)	$159.6B
Gilead Sciences (GILD)	$140.8B
Vertex Pharmaceuticals (VRTX)	$118.7B
Bristol Myers Squibb (BMY)	$90B
CSL (CSLLY)	$82.4B
GSK (GSK)	$76.6B
Regeneron Pharmaceuticals (REGN)	$60.3B
Alnylam Pharmaceuticals (ALNY)	$52.7B
Argenex SE (ARGX)	$41.2B
BioNTech SE (BNTX)	$25.8B
Royalty Pharma (RPRX)	$20.9B
Insmed (INSM)	$20.6B
Biogen (BIIB)	$19.3B
Illumina (ILMN)	$15B
Incyte (INCY)	$14.8B
Genmab (GNMSF)	$14.7B
Genmab (GMAB)	$14B
BioMarin Pharmaceutical (BMRN)	$11.1B
QIAGEN (QGEN)	$11.1B
Moderna (MRNA)	$10.7B
Ascendis Pharma (ASND)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Exelixis (EXEL)	$10B
Exact Sciences (EXAS)	$9B
Verona Pharma American Depositary Share (VRNA)	$9B
Bio-Techne Corp (TECH)	$8.6B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$7.7B
Halozyme Therapeutics (HALO)	$7.3B